Form 4: Organon & Co. Executive Aaron Falcione Reports Stock Option Grant and RSU Vesting

Aaron Falcione, Chief Human Resources Officer of Organon & Co., reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

Summary

• On March 29, 2025, Aaron Falcione, Chief Human Resources Officer of Organon & Co., filed a Form 4.
• The filing reports transactions related to Organon & Co. common stock.
• Falcione was granted stock options for 165,016 shares, vesting in three equal installments starting March 31, 2026.
• He also received 33,579 Restricted Stock Units (RSUs) that will vest in three equal installments starting March 31, 2026.
• Additionally, RSUs granted in previous years vested on March 31, 2025.
• These included one-third of the RSUs granted on March 29, 2024 (8,421 units), one-third of the RSUs granted on March 31, 2023 (6,732 units), and the final third of the RSUs granted on March 31, 2022 (3,579 units).
• The transactions resulted in Falcione beneficially owning 57,473.661 shares of common stock following the reported transactions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning executive interests with company performance. There are no immediate negative implications.

Positives

• The grant of stock options and RSUs to a key executive aligns their interests with the long-term performance of the company.
• The vesting schedule of the stock options and RSUs encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the stock options and RSUs extend to March 2028.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings and transactions of company insiders. This filing indicates standard compensation practices for executives in publicly traded companies.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation tools used by publicly traded companies to incentivize and retain key executives.
• The vesting schedules described in the document (three equal installments over three years) are typical for such grants.
• Comparing the size of the grant to similar companies and executive roles would require additional data on Organon's compensation strategy and industry benchmarks.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, aligning executive interests with long-term company performance.
• Employees may see this as a standard part of executive compensation, with no immediate impact on their roles.

Key Dates

Keywords

Form 4, Organon & Co., Aaron Falcione, Stock Options, Restricted Stock Units, RSU, Vesting, Beneficial Ownership, Chief Human Resources Officer